Dianthus Therapeutics, Inc. /DE/ Financing Cash Flow
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Financing Cash Flow of $749.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $10.38M, a 1727.46% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $739.41M, a 459160.87% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.88M, a 87.69% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $274.51M, a 92640.88% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for fiscal 2025 was $280.13M, a 9.59% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for fiscal 2024 was $255.62M, a 91.37% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for fiscal 2023 was $133.57M, a 38.17% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) financing activities for fiscal 2022 was $96.68M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $749.79M 10-Q · filed 2026-08-04 | $754.67M derived: sum of 3 quarters · filed 2026-08-04 | $1.03B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $739.41M 10-Q · filed 2026-05-05 | $744.29M derived: sum of 2 quarters · filed 2026-05-05 | $1.02B derived: sum of 3 quarters · filed 2026-05-05 | $1.02B derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $279.40M derived: sum of 2 quarters · filed 2026-03-09 | $279.96M derived: sum of 3 quarters · filed 2026-08-04 | $280.13M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $274.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $275.08M derived: sum of 2 quarters · filed 2026-08-04 | $275.24M 10-Q · filed 2025-11-05 | $314.92M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $729.00K 10-Q · filed 2026-08-04 | $40.41M derived: sum of 3 quarters · filed 2026-08-04 | $40.70M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $161.00K 10-Q · filed 2026-05-05 | $39.84M derived: sum of 2 quarters · filed 2026-05-05 | $40.13M derived: sum of 3 quarters · filed 2026-05-05 | $37.94M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $39.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $39.97M derived: sum of 2 quarters · filed 2026-03-09 | $37.78M derived: sum of 3 quarters · filed 2026-03-09 | $255.62M 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $296.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.90M derived: sum of 2 quarters · filed 2025-11-05 | $215.95M 10-Q · filed 2025-11-05 | $211.08M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $215.65M 10-Q · filed 2025-08-07 | $210.79M derived: sum of 3 quarters · filed 2025-08-07 | $349.23M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $217.85M 10-Q · filed 2025-05-12 | $212.98M derived: sum of 2 quarters · filed 2025-05-12 | $351.42M derived: sum of 3 quarters · filed 2025-05-12 | $351.42M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $133.57M derived: sum of 2 quarters · filed 2025-03-11 | $133.57M derived: sum of 3 quarters · filed 2025-03-11 | $133.57M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $138.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $138.44M derived: sum of 2 quarters · filed 2024-11-07 | $138.44M 10-Q · filed 2024-11-07 | $138.44M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-08-08 | $96.63M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $96.63M derived: sum of 3 quarters · filed 2024-05-09 | $96.68M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $96.63M derived: sum of 2 quarters · filed 2024-03-21 | $96.68M derived: sum of 3 quarters · filed 2024-03-21 | $96.68M 10-K · filed 2024-03-21 | $2.88M 10-K · filed 2023-03-23 | |
| 2022-09-30 | $96.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $96.68M derived: sum of 2 quarters · filed 2023-11-09 | $96.68M 10-Q · filed 2023-11-09 | $2.81M 10-Q · filed 2022-11-03 | $22.11M derived: sum of 4 quarters · filed 2023-12-21 | |
| 2022-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $49.00K 10-Q · filed 2023-08-03 | -$74.52M derived: sum of 3 quarters · filed 2023-12-21 | -$74.31M derived: sum of 4 quarters · filed 2023-12-21 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | -$74.56M derived: sum of 2 quarters · filed 2023-12-21 | -$74.36M derived: sum of 3 quarters · filed 2023-12-21 | $14.49M derived: sum of 4 quarters · filed 2023-12-21 | ||
| 2021-12-31 | -$74.56M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | -$74.36M derived: sum of 2 quarters · filed 2023-12-21 | $14.49M derived: sum of 3 quarters · filed 2023-12-21 | $14.91M 8-K · filed 2023-12-21 | $89.60M 10-K · filed 2022-03-08 | |
| 2021-09-30 | $203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $89.06M derived: sum of 2 quarters · filed 2022-11-03 | $89.48M 10-Q · filed 2022-11-03 | $90.66M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $88.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $89.27M 10-Q · filed 2022-08-04 | $90.45M derived: sum of 3 quarters · filed 2022-08-04 | $90.29M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $418.00K 10-Q · filed 2022-05-16 | $1.60M derived: sum of 2 quarters · filed 2022-05-16 | $1.44M derived: sum of 3 quarters · filed 2022-05-16 | $67.03M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.02M derived: sum of 2 quarters · filed 2022-03-08 | $66.61M derived: sum of 3 quarters · filed 2022-03-08 | $67.74M 10-K · filed 2022-03-08 | ||
| 2020-09-30 | -$159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $65.44M derived: sum of 2 quarters · filed 2021-11-04 | $66.56M 10-Q · filed 2021-11-04 | $67.47M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $65.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $66.72M 10-Q · filed 2021-08-05 | $67.63M derived: sum of 3 quarters · filed 2021-08-05 | $67.73M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $1.12M 10-Q · filed 2021-05-06 | $2.04M derived: sum of 2 quarters · filed 2021-05-06 | $2.13M derived: sum of 3 quarters · filed 2021-05-06 | $62.86M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $1.01M derived: sum of 2 quarters · filed 2021-03-03 | $61.73M derived: sum of 3 quarters · filed 2021-03-03 | $62.30M 10-K · filed 2021-03-03 | ||
| 2019-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $60.82M derived: sum of 2 quarters · filed 2020-11-05 | $61.38M 10-Q · filed 2020-11-05 | $60.91M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $60.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $61.29M 10-Q · filed 2020-08-06 | $60.81M derived: sum of 3 quarters · filed 2020-08-06 | $60.08M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $563.00K 10-Q · filed 2020-05-07 | $87.00K derived: sum of 2 quarters · filed 2020-05-07 | -$644.00K derived: sum of 3 quarters · filed 2020-05-07 | $142.88M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | -$476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | -$1.21M derived: sum of 2 quarters · filed 2020-03-03 | $142.32M derived: sum of 3 quarters · filed 2020-03-03 | $142.15M 10-K · filed 2020-03-03 | ||
| 2018-09-30 | -$731.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $142.80M derived: sum of 2 quarters · filed 2019-11-13 | $142.62M 10-Q · filed 2019-11-13 | $142.62M derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2018-06-30 | $143.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $143.35M 10-Q · filed 2019-08-08 | $143.35M derived: sum of 3 quarters · filed 2020-03-03 | $145.35M derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2018-03-31 | -$175.00K 10-Q · filed 2019-05-09 | -$175.00K derived: sum of 2 quarters · filed 2020-03-03 | $1.82M derived: sum of 3 quarters · filed 2020-03-03 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $2.00M derived: sum of 2 quarters · filed 2020-03-03 | $71.49M 10-K · filed 2020-03-03 | |||
| 2017-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $71.49M 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | $69.49M 10-Q · filed 2018-08-09 | |||||
| 2016-12-31 | $10.71M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |